Two years without OTC switches in the US soon could seem like the distant past after the Food and Drug Administration on one day announced its first approval of nonprescription sales for two ingredients – diclofenac sodium topical gel and olopatadine HCl ophthalmic solution/drops.
The agency on 14 February announced it approved a supplemental new drug application from GlaxoSmithKline PLC for OTC sales...







